The incidence for age group 0-18 yr standardized to the world population is remarkably higher in Slovenia than in the Republic of Srpska. Further follow-up and investigations are needed to explain the high difference in incidence of T1DM between the two geographically related countries.

Background/Aim. The Professional System of Continuous Glucose Monitoring, the iPro?2 CGM System (Medtronic) is designed to be worn together with a glucose sensor with an electrode inserted into the subcutaneous tissue, up to 7 days, without insight into the current level of glycemia. After reading data from the iPro?2 device, a realistic picture of the glycemia movement during the period of wearing the device is obtained. The aim of the study was to examine whether objective measurement information collected through the use of professional continuous glucose monitoring (CGM) contribute to improved metabolic control in children with type 1 diabetes mellitus who are on the multiple daily insulin injections (MDI). Methods. The study was conducted on 24 patients (14 girls) aged 5 to 18 years, with an average age 12 ? 3.3 years, in the period from June to December 2016 in the Clinic of Pediatrics, University Clinical Center of the Republic of Srpska in Banja Luka. Glycated hemoglobin (HbA1c) was measured in the laboratory at the start of the trial and 3 months afterwards in order to determine the effect of wearing professional iPro?2 on metabolic control, and then three months later, to test for the long-lasting effects in the absence of iPro?2 monitoring. Results. The initial HbA1c was 7.78 ? 1.17% (min: 5.50%; max: 10.00%). After 3 months, HbA1c showed a statistically significant decrease to 7.34 ? 0.84% (min: 5.60%, max: 8.90%). At the six-month follow-up visit, without implementing professional CGM in the meantime, a significant increase in HbA1c was reached, with the average value of 7.68% ? 0.83% (min: 5.50%, max: 9.10%). Conclusion. This study shows that carrying a professional CGM for 7 days per month, 3 months continuously is associated with certain improvement of metabolic control in children with diabetes who are on MDI without increasing risks of hypoglicemia.

No abstract

Poremećaji metabolizma kalcijuma i magnezijuma nisu rijetki u novorođenačkom uzrastu. Hipokalcemijai hipomagneziemija se javlja u brojnim stanjima koji su vezani za poremećaj metabolizma vitamina D i paratireoidnoghormona (PTH) ili sa nedovoljnim uvosom kalcija i magnezija. Najčešće se otkriva kod novorodjenčadi majki sa diabetesmelitusom, novorođenčadi sa malom tjelesnom masom, kod prematurusa, novorođenčadi sa ranom i kasnom tetanijomi konvulzijama, u malapsortivnom sindromu. Neonatalna hipokalcemija se definiše kao vrijednost ukupnog kalcija ispod1,76 mml/l za prematurusa i ispod 2 mmol za terminsko, ili kada je vrijednost jonizovanog kalcija 0.75 odnosno 1,1mmol/l. Hipomagneziemija se definiše kao koncentracija magnezijuma niža od 1,2 mg/dl(0,75 mmol/L).

M N OPQR *S TUVS RW )VQXRYR 4TZRQR -RXTS ZVON [W 3QR\RYR ]RMN [ 8RYN [W _PỲR ]N M S ZVON [ bcd ef cgh ijklm no klpq rjrst u q v jkw skx jv t uyr p klo rz { p lk| |k{ uz sv yu z r }v z w ṽsk v |o k k z pk~rjr z r skjv w uo rv t z yv kw o u|rr v yk{ v yr}v t rr |k{ uz w v su z rk sr { pv r ju v lo pxv ko xrsz yv z v z w uv r v t r|uw uz u{ v w pz ykl k|k{ t u{ v kl }v z w ṽsu v |o k u usx{ z w v } v |o kz v z o u{ rw ul lv r|uw uz t u srtu r uyz w o rp{ ksr{ sr yk{ v yr}v t r v { t o rlrm t u |v k pw jo lv w v lr { v kz w kt v yko u{ r}v t r v up z w uusr k w uust r { psv psy}v t r v spw o v w v jskx z w rw pz r z r jo v t ulskz w v r x{ v yuv t u lk|v t usv yksw v spv o rsv x{ pyk sv ksv w ko v sxk ykl |k{ uz sv yr z r p up|{ v }v o z ykt rw uo v t r{ v uw klum ykl |k{ uz sv yr z r }v z w ṽsk v |o k k p o rz w r kl lk xklv sr t u jo usk yksw v spv o rsk o rust u x{ pyk u w kyk z ulklsujskx sk ust r po urt r v no k ulw o ksv } v sv ul k|v t usu jo v t ulskz w v z p yko u{ v o rsu z r jo v t ulskz w v r { psv psy}v t r v z w rst r po rst uskz w v |k{ uz sv yr u p{ w rw v m jo v t ulskz w v x{ v yuv t u lk|v t usu yksw v spv o sk x{ pyk sv ksv w ko sv sxk z p p lv o uyw skt suxrw v jskt yko u{ r}v t v z r z w uusk k w uust r { psv psy}v t r v spw o v w v jsv z w rw pz k ykl v z v w v jrsv |k{ uz sv yr ry{ t p~rym z w uus ko uurt r uw r|k{ v r x{ pyk u t u sr~rt rs o ulv yw ko k w uust r { psv psy}v t r ykl |k{ uz sv yr z r }v z w ṽsk v |o k k e ¡ ¢ e¢ h }v z w ṽsr v |o k r { psu psy}v t u yksw v spv o rsv ksv w ko v sx x{ pyk u

SummaryIntroduction. The automatic suspension of the insulin pump and discontinuation of insulin delivery in case of hypoglycemia is one of the features of Veo insulin pump when it is connected with the sensor used for continuous monitoring of glycemia (CGM). This type of therapy is currently considered to be the best one for achieving a good metabolic control in children with type 1 diabetes mellitus. The objective of the study was to check whether the use of an option for automatic suspension in case of hypoglycemia and combined bolus affects the metabolic control in children with type 1 diabetes mellitus using the insulin pump for a three-month period.